Modern Management of Mantle Cell Lymphoma
New combination therapies and immune-redirecting treatments are improving outcomes for mantle cell lymphoma, a previously hard-to-treat blood cancer.
An ASCO Educational Book review by authors from Memorial Sloan Kettering, LMU Munich, and Oxford synthesizes the current MCL treatment landscape from MIPI/Ki-67 risk stratification through BTKi-integrated frontline therapy, maintenance rituximab, and emerging T-cell-redirecting therapies (CAR-T, bispecifics) for relapsed/refractory disease. This guideline-proximal educational resource reflects state-of-practice consensus for a biologically heterogeneous B-cell malignancy.
What the study was
- Study design
- Evidence-based educational review (ASCO Educ Book)
- Population
- Mantle cell lymphoma patients across fitness levels and risk groups
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- American Society of Clinical Oncology Educational Book
Why it surfaced
ASCO Educational Book review from leading MCL centers (MSK, LMU, Oxford) covering comprehensive treatment landscape including BTKi, CAR-T, and bispecifics; guideline-proximal and highly relevant to hematologic malignancy watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.